Search

Author/Creator d'Hondt, E.

1. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. (February 2022)

Authors:
Rodríguez-Abreu, D.; Cobo, M.; García-Román, S.; Viteri-Ramírez, S.; Jordana-Ariza, N.; García-Peláez, B.; Reguart, N.; Aguilar, A.; Codony-Servat, J.; Drozdowskyj, A.; Molina-Vila, M.A.; d'Hondt, E.; Rosell, R.
Journal:
Lung cancer
Issue:
Volume 164(2022)
Page Start:
8
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search